PMID- 32832553
OWN - NLM
STAT- MEDLINE
DCOM- 20210423
LR  - 20220416
IS  - 2314-6141 (Electronic)
IS  - 2314-6133 (Print)
VI  - 2020
DP  - 2020
TI  - Valuable Role of Neutrophil CD64 and Highly Sensitive CRP Biomarkers for 
      Diagnostic, Monitoring, and Prognostic Evaluations of Sepsis Patients in Neonatal 
      ICUs.
PG  - 6214363
LID - 10.1155/2020/6214363 [doi]
LID - 6214363
AB  - BACKGROUND: Neonatal sepsis (NS) is a very critical medical situation associated 
      with high morbidities and mortalities. There is an utmost need for a new tool 
      helping in early diagnosis and proper management of sepsis neonates. Neutrophil 
      CD64 (nCD64) shows a very promising value in this concerning issue. AIM: Evaluate 
      the diagnostic, monitoring, and prognostic performances of nCD64 and highly 
      sensitive CRP (hs-CRP) in NS as well as the possible best panel of biomarkers 
      that can achieve the most desirable results. METHODS: Patients were enrolled from 
      three neonatal intensive care units (NICUs) (n = 121 patients) and classified 
      according to their initial sepsis evaluation into three groups: disease control 
      group (n = 30), proven sepsis group (n = 17), and clinical sepsis group (n = 74). 
      Laboratory evaluation included hs-CRP, complete blood count (CBC), and blood 
      culture in addition to nCD64 (done by flow cytometry technique). Besides the 
      diagnostic evaluations, follow-up evaluations were done for 40 patients after 
      five days from the first time; patients were reclassified according to their 
      outcome into the improved sepsis neonates' group (n = 26) and sepsis neonates 
      without improvement (n = 14). RESULTS: Significant increase in nCD64 and hs-CRP 
      results were present in sepsis groups compared to the disease controls (P < 
      0.001); nCD64 at 43% cutoff value could detect the presence of sepsis with 85.6% 
      sensitivity and 93% specificity. Additionally, delta change percentage (dC%) 
      between improved sepsis neonates and sepsis neonates without improvement showed a 
      significant difference in the levels of both nCD64 (P < 0.001) and hs-CRP (P = 
      0.001). CONCLUSION: Besides the promising diagnostic performance documented by 
      nCD64 which is higher than the other laboratory sepsis biomarkers used routinely 
      in NICUs, nCD64 has a valuable role in sepsis patients' monitoring and prognostic 
      evaluation. hs-CRP was moderate in its diagnostic and monitoring results being 
      less than that achieved by nCD64. Combined measurement of nCD64% and hs-CRP gives 
      better diagnostic and monitoring performance than that achieved by any of them 
      alone.
CI  - Copyright (c) 2020 Heba E. Hashem et al.
FAU - Hashem, Heba E
AU  - Hashem HE
AUID- ORCID: 0000-0002-2996-7309
AD  - Clinical Pathology Department, Faculty of Medicine, Ain Shams University, Egypt.
FAU - El Masry, Sherin A
AU  - El Masry SA
AD  - Clinical Pathology Department, Faculty of Medicine, Ain Shams University, Egypt.
FAU - Mokhtar, Amira M
AU  - Mokhtar AM
AD  - Clinical Pathology Department, Faculty of Medicine, Ain Shams University, Egypt.
FAU - Ismail, Eman A
AU  - Ismail EA
AUID- ORCID: 0000-0002-1162-0171
AD  - Clinical Pathology Department, Faculty of Medicine, Ain Shams University, Egypt.
FAU - Abdelaal, Noureldin M
AU  - Abdelaal NM
AD  - Neonatology Department, Faculty of Medicine, Ain Shams University, Egypt.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
DEP - 20200807
PL  - United States
TA  - Biomed Res Int
JT  - BioMed research international
JID - 101600173
RN  - 0 (Biomarkers)
RN  - 0 (Receptors, IgG)
RN  - 9007-41-4 (C-Reactive Protein)
SB  - IM
MH  - Biomarkers/blood
MH  - C-Reactive Protein/*metabolism
MH  - Female
MH  - *Flow Cytometry
MH  - Humans
MH  - Infant, Newborn
MH  - Infant, Premature
MH  - *Intensive Care Units, Neonatal
MH  - Male
MH  - Monitoring, Physiologic
MH  - Neutrophils/*metabolism
MH  - Prognosis
MH  - Prospective Studies
MH  - Receptors, IgG/*blood
MH  - *Sepsis/blood/diagnosis
PMC - PMC7429763
COIS- No conflict of interest was declared.
EDAT- 2020/08/25 06:00
MHDA- 2021/04/24 06:00
PMCR- 2020/08/07
CRDT- 2020/08/25 06:00
PHST- 2020/05/04 00:00 [received]
PHST- 2020/07/07 00:00 [revised]
PHST- 2020/07/20 00:00 [accepted]
PHST- 2020/08/25 06:00 [entrez]
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2021/04/24 06:00 [medline]
PHST- 2020/08/07 00:00 [pmc-release]
AID - 10.1155/2020/6214363 [doi]
PST - epublish
SO  - Biomed Res Int. 2020 Aug 7;2020:6214363. doi: 10.1155/2020/6214363. eCollection 
      2020.